On the heels of Mendus’s recent Q123 results, we take a deep dive into the company’s lead cancer vaccine candidate, vididencel, and the acute myeloid leukaemia (AML) maintenance treatment landscape. On closer inspection of the current AML pipeline and standard of care (SoC), vididencel’s clinical profile and the potential advantages associated with the vaccine’s ‘off-the-shelf’ characteristics may enable more timely and wider access of treatment to patients compared to individualised therapy app ....
23 May 2023
Mendus - Sights on vididencel (in AML) combination study
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mendus - Sights on vididencel (in AML) combination study
- Published:
23 May 2023 -
Author:
Soo Romanoff -
Pages:
8
On the heels of Mendus’s recent Q123 results, we take a deep dive into the company’s lead cancer vaccine candidate, vididencel, and the acute myeloid leukaemia (AML) maintenance treatment landscape. On closer inspection of the current AML pipeline and standard of care (SoC), vididencel’s clinical profile and the potential advantages associated with the vaccine’s ‘off-the-shelf’ characteristics may enable more timely and wider access of treatment to patients compared to individualised therapy app ....